DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/36zmdc/pituitary_acth) has announced the addition of the "Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Pituitary ACTH Hypersecretion (Cushing's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pituitary ACTH Hypersecretion (Cushing's Disease) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Alder Biopharmaceuticals Inc.
- Corcept Therapeutics Incorporated
- Cortendo AB
- Cyclacel Pharmaceuticals, Inc.
- ElexoPharm GmbH
- Ipsen S.A.
- Isis Pharmaceuticals, Inc.
- Novartis AG
- Orphagen Pharmaceuticals, Inc.
- Pfizer Inc.
- pasireotide LAR
- Peptides to Antagonize ACTH Receptor for Cushing's Syndrome
- Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease
- Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease
- Small Molecules to Inhibit CYP11B1 for Cushing's Disease and Subclinical Hypercortisolism
- Small Molecules to Modulate Cryptochrome for Metabolic and CNS Disorders
For more information visit http://www.researchandmarkets.com/research/36zmdc/pituitary_acth